Meeting
2015 ASCO Annual Meeting
Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902).
Authors
Thomas Hutson
Texas Oncology–Baylor Charles A. Sammons Cancer Center, Dallas, TX
Thomas Hutson , Dimitry Nosov , Piotr Tomczak , Igor Bondarenko , Oleg N. Lipatov , Cora N. Sternberg , Michael N. Needle , Tim Eisen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT01030783, NCT01076010, NCT01369433
Citation
J Clin Oncol 33, 2015 (suppl; abstr 4557)
DOI
10.1200/jco.2015.33.15_suppl.4557
Abstract #
4557
Poster Bd #
231
Abstract Disclosures
Similar Posters
Poster
2013 Genitourinary Cancers Symposium
Subgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC).
First Author: Thomas E. Hutson
Poster
2013 Genitourinary Cancers Symposium
Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib.
First Author: Robert John Motzer
Poster
2011 ASCO Annual Meeting
A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC).
First Author: E. Angevin
Poster
2024 ASCO Genitourinary Cancers Symposium
Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC).
First Author: Andrew Johns